Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

POET Technologies Inc.

3.207 Posts
Pagina: «« 1 ... 146 147 148 149 150 ... 161 »» | Laatste | Omlaag ↓
  3. forum rang 10 DeZwarteRidder 22 november 2019 08:55

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 25 apr 2024

    • Aanbevelingen

      Ontvangen: 20848

      Gegeven: 9463

    •    Aantal posts: 96.774

    POET Technologies Reports Third Quarter 2019 Financial Results
    Email Print Friendly Share
    November 21, 2019 17:28 ET | Source: POET Technologies Inc.

    SAN JOSE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (OTCQX: POETF; TSX Venture: PTK), the designer and developer of the POET Optical Interposer and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today reported its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2019. The Company’s financial results as well as the Management Discussion and Analysis for the periods have been filed on SEDAR.

    Third Quarter and Recent Highlights:

    Revenue, including contribution from discontinued operations, was US$1.2 million compared to US$1.4 million in Q2 2019; revenue for the 9 months ended September 30, 2019 increased by 88% to US$4.4 million from US$2.3 million in the same period in 2018;
    Gross margin, including contribution from discontinued operations, increased to 71% from 70% in Q2 2019; gross margin for the 9 months ended September 30, 2019 increased to 74% from 59% in 2018;
    The fifth and final tranche of Convertible Debenture private placement was closed for gross proceeds of US$137,000 (C$182,000), bringing the total capital raised through Convertible Debentures to approximately US$3.7 (C$5.0) million;
    The Company held its Annual General Meeting on September 20, 2019 in Toronto at which its current slate of directors was re-elected for another term; a Special Meeting of the Shareholders was also held on October 24, 2019 at which 99% of shareholders voted in favor of the sale of DenseLight;
    The Company signed a definitive agreement for the sale of DenseLight on August 20, 2019 and completed the sale on November 8, 2019. The first tranche payment of US$8 million was received on November 8, 2019. Two additional tranche payments of US$13 million and US$5 million are expected to be received on or before December 31, 2019 and May 31, 2020, respectively. In connection with the sale, the Company recognized a gain of approximately US$10 million;
    The Company repaid its debt in full to the secured lenders and subsequently all security interests in the assets of POET were discharged;
    Announced the appointment of Vivek Rajgarhia as President and General Manager of the Company, while Suresh Venkatesan added the title of Chairman to his existing role as CEO.

  4. forum rang 10 DeZwarteRidder 22 november 2019 08:56

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 25 apr 2024

    • Aanbevelingen

      Ontvangen: 20848

      Gegeven: 9463

    •    Aantal posts: 96.774

    Financial Summary

    Due to the sale of its wholly owned subsidiary, DenseLight Semiconductor Pte Ltd (“DenseLight”), the Company is required to report the activities of DenseLight as a discontinued operation with effect from January 1, 2019. The financial statements filed today reflect this classification. The Company operated as a single integrated entity until November 8, 2019, the Closing Date of the sale transaction. For comparative purposes, all financial data below represent the combined results from both continuing and discontinued operations and is presented on a proforma, non-IFRS basis in the table at the bottom of this press release. The required IFRS presentation of the Company’s Financial Statements can be found in its recent filings on SEDAR.

    For the third quarter of 2019, revenue, including contribution from discontinued operations, was US$1.2 million, compared with US$1.4 million in the second quarter of 2019 and US$0.9 million in the third quarter of 2018. The quarterly decrease in revenue resulted from a slowing of device sales from DenseLight resulting from weaker industry-wide demand. Gross margin for the third quarter of 2019 was 71% compared to 70% in the preceding quarter but showed substantial improvement over the 59% recorded in the same quarter last year, due to the higher proportion of NRE in the revenue mix.

    Consolidated net loss, including discontinued operations, in the third quarter of 2019 was (US$2.9) million, or ($0.01) per share, compared with a net loss of (US$3.8) million, or ($0.01) per share, in the second quarter of 2019 and a net loss of (US$4.9) million, or ($0.02) per share, in the third quarter of 2018. The net loss in the third quarter of 2019 included non-cash stock-based compensation of US$0.9 million, non-cash depreciation and amortization of US$42,000, compared with non-cash stock-based compensation and non-cash depreciation and amortization of US$0.8 million and US$35,000, respectively, in the preceding quarter. Non-cash stock-based compensation and depreciation and amortization were US$1.1 million and US$0.6 million, respectively, in the third quarter of 2018. The reduction of depreciation and amortization expense in 2019 is a result of the classification of the DenseLight subsidiary as discontinued operations, for which depreciation and amortization expense is not recognized.

    During the third quarter of 2019, the Company had non-cash debt-related finance costs of US$235,000 compared to US$164,000 in the second quarter of 2019. There were no debt-related finance costs in the third quarter of 2018. Third quarter 2019 interest paid on funds borrowed amounted to US$209,000 compared to US$137,000 in the second quarter of 2019. No interest was paid in third quarter of 2018.

    On a non-IFRS basis, cash operating loss in the third quarter of 2019 was (US$1.9) million compared to (US$2.8) million in the prior quarter and (US$3.0) million during the same quarter in 2018.

    The Company intends to continue reporting revenues consolidated with the DenseLight operation through November 8, 2019, since the bulk of its R&D, production and sales activities were conducted there. With the closing now completed, DenseLight is expected to remain a key development partner and supplier to POET.
  12. [verwijderd] 15 februari 2020 13:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    In de Kuip, meestal tandenknarsend...

    Zonder gekheid, ik heb de afgelopen jaren prive een moeilijke tijd gehad.

    Ineens dacht ik: ik kijk weer eens op IEX. Gek eigenlijk. Wie begrijpt dat?
  14. veer62 15 februari 2020 17:40

    • veer62

      Lid sinds: 21 jul 2009

      Laatste bezoek: 14 sep 2023

    • Aanbevelingen

      Ontvangen: 138

      Gegeven: 29

    •    Aantal posts: 2.923

    quote:

    doewap schreef op 15 februari 2020 14:01:

    Ik vraag me nu nog wel een paar dingen af:

    1. waar is veer?
    2. wie is $emi?
    3. Is DZR soms gedraaid?
    hoi doewap, dit is nou een leuke verrassing.ik hoop dat het nu beter met je gaat.heb nog eventjes gedacht,het zou toch niet.pffffff maar gelukkig niet .man man man veer is blij dat je weer wat van je laat horen.
  18. [verwijderd] 16 februari 2020 13:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    doewap schreef op 16 februari 2020 12:24:

    Ik heb nog
    Waterstof gaat nu eindelijk serieus worden, heb je nog Pluggen?

    Maar misschien wil je wel meer:
    www.iex.nl/Forum/Topic/1329984/1/Foru...

    Weet niet of biotech jou ding is maar ik vindt dit heel interessant. Veelbelovend innovatief bedrijf, goede bijdrages in de draad (m.n. Tom3) en ook zelfs op het Yahooforum.
    Het is toch kutweer, ik zou zeggen lees je wat in tot 16.45 uur.
    :-).
  19. [verwijderd] 16 februari 2020 14:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik kijk shorttrack.
    Doe niet veel. Altijd slechte timing gehad. Veel goede bedrijven gevonden, weinig geprofiteerd.

    Geen PLUG meer. Ook geen Ballard...
3.207 Posts
Pagina: «« 1 ... 146 147 148 149 150 ... 161 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.270
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.892
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.307
Aedifica 2 829
Aegon 3.257 320.040
AFC Ajax 537 7.017
Affimed NV 2 5.752
ageas 5.843 109.777
Agfa-Gevaert 13 1.856
Ahold 3.536 73.980
Air France - KLM 1.024 34.308
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.767
Alfen 12 16.226
Allfunds Group 3 1.185
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 327
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.245
AMG 965 125.633
AMS 3 73
Amsterdam Commodities 303 6.516
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.110
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.590
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.105
Aroundtown SA 1 176
Arrowhead Research 5 9.260
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.646
ASML 1.762 76.825
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 332
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.649
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.660

Macro & Bedrijfsagenda

  1. 26 april

    1. Bank of Japan rentebesluit 0% (onveranderd) volitaliteit verwacht
    2. Corbion Q1-cijfers
    3. Signify Q1-cijfers
    4. IMCD Q1-cijfers
    5. Basic-Fit trading update Q1 en jaarvergadering
    6. Total Energies Q1-cijfers
    7. Beursgang CVC (verwacht)
    8. ABN Amro € 0,89 ex-dividend
    9. ASML €1,75 ex-dividend
    10. Vopak €1,50 ex-dividend
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda